* Akoya Biosciences Inc reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of eight analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -26 cents to -16 cents per share.

* Revenue fell 25.1% to $18.81 million from a year ago; analysts expected $25.42 million.

* Akoya Biosciences Inc's reported EPS for the quarter was a loss of 21 cents​.

* The company reported a quarterly loss of $10.53 million.

* Akoya Biosciences Inc shares had risen by 15.1% this quarter and lost 35.9% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Akoya Biosciences Inc is 4.00 This summary was machine generated from LSEG data November 15 at 02:09 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.20 -0.21 Missed

Jun. 30 2024 -0.29 -0.27 Beat

Mar. 31 2024 -0.29 -0.48 Missed

Dec. 31 2023 -0.27 -0.22 Beat